--Dow Keeps Quarterly Dividend at $0.70 Per Share; Payable Sept. 13 to Shareholders of Record on Aug. 30-November 2024-www.financetom.com

--Dow Keeps Quarterly Dividend at $0.70 Per Share; Payable Sept. 13 to Shareholders of Record on Aug. 30

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

--Dow Keeps Quarterly Dividend at $0.70 Per Share; Payable Sept. 13 to Shareholders of Record on Aug. 30

Aug 14, 2024 2:11 PM

04:52 PM EDT, 08/14/2024 (MT Newswires) --

Price: 52.50, Change: -0.26, Percent Change: -0.49

Previous page： US Treasury Dept issues sanctions related to Salt Typhoon hack Next page： Bausch Health Notes Xifaxan 550 mg Selected For Medicare 2nd Round Negotiations

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

US Treasury Dept issues sanctions related to Salt Typhoon hack

Jan 17, 2025

WASHINGTON (Reuters) - The U.S. Treasury department on Friday issued cyber-related sanctions related to the Salt Typhoon hack on Singaporean Yin Kechen and cybersecurity company Sichuan Juxinhe Network Technology Co., according to a statement. ...

Bausch Health Notes Xifaxan 550 mg Selected For Medicare 2nd Round Negotiations

Jan 17, 2025

10:27 AM EST, 01/17/2025 (MT Newswires) -- Bausch Health Companies ( BHC ) , down near 1% at last look, on Friday said the Centers for Medicare and Medicaid Services (CMS) has selected Xifaxan (rifaximin) 550 mg tablets for the second round of negotiation as part of the Inflation Reduction Act. We look forward to engaging in open and transparent...

Zai Lab's Schizophrenia Drug Application Accepted by Chinese Regulator; Shares Rise

Jan 17, 2025

10:20 AM EST, 01/17/2025 (MT Newswires) -- Zai Lab ( ZLAB ) said Friday that its new drug application for KarXT to treat adult patients with schizophrenia was accepted by China's National Medical Products Administration. The application is backed by results from a phase 1 China pharmacokinetics study, the phase 3 China study and data from global Emergent clinical programs,...

Goldman Sachs Raises CEO David Solomon's Compensation to $39 Million in 2024

Jan 17, 2025

10:23 AM EST, 01/17/2025 (MT Newswires) -- Goldman Sachs Group ( GS ) said in a regulatory filing Friday its board has approved to increase Chief Executive David Solomon's total annual compensation to $39 million in 2024 from $31 million in 2023. Solomon and Chief Operating Officer John Waldron were also given restricted stock units valued at $80 million each...